Skip to main content
Atrás
Watch Compare

OS Therapies Inc

Calidad de datos: 83%
OSTX
NYSE Manufacturing Chemicals
$1.30
▼ $0.05 (-3.70%)
Cap. Mercado: 54.02 M
Precio
$1.34
Cap. Mercado
54.02 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Debt/Equity of 0.03 — conservative balance sheet
Negative free cash flow of -14.24 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-670.19%
Below sector avg (-53.34%)
ROIC-382.41%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.03
Below sector avg (0.31)
Current Ratio0.56
Interest Coverage-13.99

Valoración

PE (TTM)
-1.88
Below sector avg (-1.47)
P/B Ratio14.85
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.9 -1.5
P/B 14.9 1.6
ROE % -670.2 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.0 0.3

Precio Objetivo de Analistas

5 analistas
Buy
Actual
$1.30
+737.5%
Objetivo
$10.89
$6.00
$8.00
$20.00
Pronóstico
P/E Futuro -4.59
EPS Futuro -$0.28
Ingresos Est. 29.71 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.28
-$0.66 – -$0.01
 29.71 M 3
FY2026 -$0.43
-$0.65 – -$0.16
 3.56 M 4

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.14 -$0.41 -192.9%
Q32025 -$0.12 -$0.21 -71.4%
Q22025 -$0.12 -$0.19 -62.9%
Q12025 -$0.09 -$0.18 -107.7%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -28.75 M
ROE -670.19% ROA -298.53%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14.24 M
ROIC -382.41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.03 Current Ratio 0.56
Interest Coverage -13.99 Asset Turnover N/A
Working Capital -1.82 M Tangible Book Value -3.23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.88 Forward P/E N/A
P/B Ratio 14.85 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -26.36%
Market Cap 54.02 M Enterprise Value 54.12 M
Per Share
EPS (Diluted TTM) -0.98 Revenue / Share N/A
FCF / Share -0.35 OCF / Share -0.35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 49.52%
SBC-Adj. FCF -16.90 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -28.75 M -8.88 M
EPS (Diluted) -0.98 -0.88
Gross Profit — —
Operating Income -28.71 M -6.81 M
EBITDA — —
R&D Expenses 16.36 M 2.84 M
SG&A Expenses — —
D&A 363,085.0 —
Interest Expense 2.05 M 2.05 M
Income Tax — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 6.84 M 5.54 M
Total Liabilities 11.86 M 4.73 M
Shareholders' Equity -6.10 M -5.24 M
Total Debt 100,000.0 100,000.0
Cash & Equivalents — —
Current Assets 332,912.0 5.53 M
Current Liabilities 11.76 M 4.63 M